SCHEMBL876246

SCHEMBL876246

c1c[nH]c(Oc2ncc[nH]2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NISCH Q9Y2I1 2/20 0.36
MTOR P42345 1/20 0.36
ADK P55263 1/20 0.36
ALOX15 P16050 1/20 0.33
TAAR1 Q96RJ0 1/20 0.32
SMPD3 Q9NY59 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
KDM4E B2RXH2 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP19A1 P11511 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
ADRA1A P35348 2/20 0.30
ADRA2A P08913 1/20 0.30
ADRA2C P18825 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5624457 0.82 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2NISCHMTORADK
SCHEMBL1983146 0.79 NISCH (0.45) ALDH1A1NISCHMTORADKTAAR1
SCHEMBL29683638 0.78
SCHEMBL8579331 0.78
SCHEMBL187790 0.78
SCHEMBL8579336 0.78
SCHEMBL6368310 0.78
SCHEMBL1145756 0.78
SCHEMBL11165626 0.76 ALDH1A1 (0.31) ALDH1A1SMN1; SMN2
SCHEMBL5969677 0.76 NISCH (0.48) ALDH1A1SMN1; SMN2NISCHMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250296922-A1 POLYSUBSTITUTED PYRROLIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI WENNAI THERAPEUTICS CO LTD (CN) 2025-09-25 US claimed
WO-2025021115-A1 POLYSUBSTITUTED PYRROLIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF 上海闻耐医药科技有限公司 2025-01-30 WO claimed
US-5240964-A Adding piperazine catalyst with imidazole, triazine or amidine compound to create difference in gas evolution between inner and outer parts of plastic liquid TOKYO SEAT CO., LTD. (JP) 1993-08-31 US claimed
EP-0358377-B1 BIS IMIDAZOLE ETHERS AS METAL DEACTIVATORS EXXON RESEARCH AND ENGINEERING COMPANY (US) 1993-04-28 EP claimed
US-5141684-A Using catalyst which creates difference in gas evolution between inner and outer parts of plastic liquid in mold to form high density layer on outer surface TOKYO SHEET CO., LTD. (JP) 1992-08-25 US claimed
US-5139713-A One step molding, high density surfaces TOKYO SHEET CO., LTD. (JP) 1992-08-18 US claimed
US-5011935-A Imidazole ether compounds SAN-APRO LIMITED (JP) 1991-04-30 US claimed
JP-4298519-A None JP disclosed
JP-3033120-A None JP disclosed
JP-2117665-A None JP disclosed
JP-2160768-A None JP disclosed
US-12612383-B2 Polysubstituted pyrrolidine derivative, preparation method therefor and use thereof SHANGHAI WENNAI THERAPEUTICS CO., LTD. (CN) 2026-04-28 US disclosed
US-20250296922-A1 POLYSUBSTITUTED PYRROLIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI WENNAI THERAPEUTICS CO LTD (CN) 2025-09-25 US disclosed
US-4312880-A COMBATING PHYTOPATHOGENS BAYER AKTIENGESELLSCHAFT (DE) 1982-01-26 US disclosed
EP-0040366-A1 Imidazolyl-vinyl ketones and carbinols, process for their preparation and their use as fungicides BAYER AG (DE) 1981-11-25 EP disclosed
EP-0023614-A1 Antimycotic compositions containing imidazolylenol ethers, their preparation and their use BAYER AG (DE) 1981-02-11 EP disclosed
EP-0023651-A1 Imidazolyl-enol ethers, process for their preparation and their use as fungicides BAYER AG (DE) 1981-02-11 EP disclosed
US-4224452-A HYDROLYSIS ETHYL CORPORATION (US) 1980-09-23 US disclosed
US-4224452-A HYDROLYSIS ETHYL CORPORATION (US) 1980-09-23 US disclosed
JP-H00333120-A 0001-01-01 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250296922-A1 POLYSUBSTITUTED PYRROLIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF SCN8A, SCN11A, TRPV1 ALDH1A1 2001/4885SMN1; SMN2 1522/4885NISCH 426/4885
US-12612383-B2 Polysubstituted pyrrolidine derivative, preparation method therefor and use thereof SCN8A, SCN11A, TRPV1 ALDH1A1 2204/4885SMN1; SMN2 1714/4885NISCH 982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.